AR004445A1 - Una composicion inmunogenica, una dosis unitaria, un metodo para producir la composicion, un kit para producir la composicion, una poblacion de celulas,uso de dicha poblacion celular y una preparacion combinada - Google Patents

Una composicion inmunogenica, una dosis unitaria, un metodo para producir la composicion, un kit para producir la composicion, una poblacion de celulas,uso de dicha poblacion celular y una preparacion combinada

Info

Publication number
AR004445A1
AR004445A1 ARP970104701A ARP970104701A AR004445A1 AR 004445 A1 AR004445 A1 AR 004445A1 AR P970104701 A ARP970104701 A AR P970104701A AR P970104701 A ARP970104701 A AR P970104701A AR 004445 A1 AR004445 A1 AR 004445A1
Authority
AR
Argentina
Prior art keywords
composition
produce
cell population
lymphocytes
tumor
Prior art date
Application number
ARP970104701A
Other languages
English (en)
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of AR004445A1 publication Critical patent/AR004445A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se relaciona con el campo de la inmulología celular y la terapia contra el cáncer. La presente invención proporciona unacomposición inmunogénica adecuada para ser administrada a un humano y métodos para producirla. La composición contiene una combinación efectiva de linfocitosestimulados alogénicos al humano y una fuente de antígeno tumoral que se asocia con el cáncer a tratar. Los linfocitos alogénicos pueden ser estimuladoscombinándolos o co-cultivándolos con leucocitos alogénicos a los linfocitos. La composición inmunogénica se administra en un sitio distante del tumorprimario, activándose una respuesta inmunológica antitumoral celular sistémica Este enfoque supera la naturaleza refractaria inherente del sistemainmunológico a la estimulación por antígenos tumorales, generando una respuesta del huésped y mejorando potencialmente el resultado clínico.
ARP970104701A 1996-10-11 1997-10-13 Una composicion inmunogenica, una dosis unitaria, un metodo para producir la composicion, un kit para producir la composicion, una poblacion de celulas,uso de dicha poblacion celular y una preparacion combinada AR004445A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2854896P 1996-10-11 1996-10-11

Publications (1)

Publication Number Publication Date
AR004445A1 true AR004445A1 (es) 1998-12-16

Family

ID=21844058

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970104701A AR004445A1 (es) 1996-10-11 1997-10-13 Una composicion inmunogenica, una dosis unitaria, un metodo para producir la composicion, un kit para producir la composicion, una poblacion de celulas,uso de dicha poblacion celular y una preparacion combinada

Country Status (13)

Country Link
US (1) US6207147B1 (es)
EP (1) EP0930887B1 (es)
JP (1) JP2001509135A (es)
KR (1) KR20000049096A (es)
CN (1) CN1237909A (es)
AR (1) AR004445A1 (es)
AT (1) ATE229810T1 (es)
AU (1) AU743855B2 (es)
BR (1) BR9712988A (es)
CA (1) CA2267157C (es)
DE (1) DE69718029T2 (es)
NO (1) NO991691L (es)
WO (1) WO1998016238A2 (es)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361332B2 (en) 1995-03-17 2008-04-22 The Regents Of The University Of California Treating tumors using implants comprising combinations of allogeneic cells
US6368593B1 (en) 1997-10-10 2002-04-09 The Regents Of The University Of California Enhanced immunogenic cell populations prepared using H2 receptor antagonists
US20080220025A1 (en) * 1995-03-17 2008-09-11 James Thompson Treating Tumors Using Implants Comprising Combinations of Allogeneic Cells
WO1998048000A2 (en) * 1997-04-23 1998-10-29 The Regents Of The University Of California A cell strain with activated anti-cancer cytotoxic activity
ATE359080T1 (de) 1997-10-10 2007-05-15 Univ California Allogene zellkombination enthaltende implantate zur krebsbehandlung
WO1999018980A1 (en) 1997-10-10 1999-04-22 Meyer Pharmaceuticals, Llc Cancer immunotherapy using allostimulated cells in a multiple sequential implantation strategy
JP4389039B2 (ja) * 1998-04-09 2009-12-24 株式会社リンフォテック アロジェニックな活性化ｃｄ４陽性細胞を主成分とする医薬組成物、およびその製造方法、ならびに該医薬組成物調製用キット
US7666609B1 (en) 1998-12-01 2010-02-23 Shanghai Cp Guojian Pharmaceutical Co. Ltd. Method and composition for diagnosis of melanocytic lesions
EP1159967B1 (en) * 1999-02-09 2008-09-10 Riken Tumor vaccines
DE60144515D1 (de) 2000-04-01 2011-06-09 Onyvax Ltd Prostata zellinien und deren verwendung
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US20080194022A1 (en) * 2000-08-03 2008-08-14 Clarke Michael F Isolation and use of solid tumor stem cells
DE10043437A1 (de) * 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
US7723111B2 (en) * 2001-03-09 2010-05-25 The United States Of America As Represented By The Department Of Health And Human Services Activated dual specificity lymphocytes and their methods of use
IL157504A0 (en) * 2001-05-11 2004-03-28 Wellstat Biologics Corp Oncolytic virus therapy
US7658926B2 (en) * 2001-09-14 2010-02-09 Opexa Pharmaceuticals, Inc. Autologous T-cell vaccines materials and methods
EP1293205A1 (en) * 2001-09-18 2003-03-19 G2M Cancer Drugs AG Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
CN100422334C (zh) * 2001-11-27 2008-10-01 内克西特股份有限公司 秀丽新杆线虫中真核生物蛋白质和核酸分子的生产
KR20020060643A (ko) * 2002-06-04 2002-07-18 김진경 타인의 면역시스템을 이용하는 암의 치료 방법
AU2003258090B2 (en) * 2002-08-08 2010-07-22 Baylor College Of Medicine Isolation and identification of T cells
US7571817B2 (en) * 2002-11-06 2009-08-11 Varco I/P, Inc. Automatic separator or shaker with electromagnetic vibrator apparatus
WO2004075855A2 (en) 2003-02-26 2004-09-10 Biomed Solutions, Llc Process for in vivo treatment of specific biological targets in bodily fluid
WO2004096244A1 (en) * 2003-05-02 2004-11-11 Md Bioalpha Co. Ltd. Method of preparing tumor vaccine for the inducement of anti-tumor activity and a pharmaceutical composition containing the same
US7807784B2 (en) 2003-06-11 2010-10-05 The University Of Chicago Increased T-cell tumor infiltration by mutant LIGHT
US7811983B2 (en) * 2003-06-11 2010-10-12 The University Of Chicago Increased T-cell tumor infiltration and eradication of metastases by mutant light
US20050019336A1 (en) 2003-07-23 2005-01-27 Dalgleish Angus George Human prostate cell lines in cancer treatment
US7696322B2 (en) * 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
AU2004280616A1 (en) * 2003-10-08 2005-04-21 Vet-Stem Inc. Methods of preparing and using stem cell compositions and kits comprising the same
US8029454B2 (en) 2003-11-05 2011-10-04 Baxter International Inc. High convection home hemodialysis/hemofiltration and sorbent system
US20050112684A1 (en) * 2003-11-21 2005-05-26 Eric Holzle Class I and Class II MHC Profiling for Social and Sexual Matching of Human Partners
EP2369014A1 (en) 2004-02-03 2011-09-28 The Regents Of The University Of Michigan Office Of Technology Transfer Compositions and methods for characterizing, regulating, diagnosing and treating cancer
US7858323B2 (en) 2004-06-09 2010-12-28 The Regents Of The University Of Michigan Phage microarray profiling of the humoral response to disease
US8257715B1 (en) 2004-08-26 2012-09-04 University Of Notre Dame Tissue vaccines and uses thereof
US9155789B2 (en) * 2005-04-25 2015-10-13 New York University Use of allogenic or syngenic major histocompatibility complex (MHC) molecules as universal adjuvants for vaccines against neoplastic disease, infection and autoimmune disease
US20090162405A1 (en) * 2006-12-14 2009-06-25 Yong Qian Proteinase-engineered cancer vaccine induces immune responses to prevent cancer and to systemically kill cancer cells
US8778360B2 (en) * 2005-10-27 2014-07-15 University Of Notre Dame Extracellular matrix cancer vaccine adjuvant
US9308252B2 (en) * 2005-10-27 2016-04-12 Cook Biotech, Inc. Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
US8778362B2 (en) 2005-10-27 2014-07-15 University Of Notre Dame Anti-tumor/cancer heterologous acellular collagenous preparations and uses thereof
US8802113B2 (en) * 2005-10-27 2014-08-12 University Of Notre Dame Extracellular matrix cancer vaccine adjuvant
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
US7723112B2 (en) * 2005-10-31 2010-05-25 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
HUE031122T2 (en) 2005-10-31 2017-07-28 Oncomed Pharm Inc Preparations and methods for the treatment of cancer based on human FZD receptors
US20070243192A1 (en) * 2006-02-21 2007-10-18 Regents Of The University Of Michigan Growth hormone receptor antagonist cancer treatment
WO2008121102A2 (en) * 2006-02-21 2008-10-09 The Regents Of The University Of Michigan Hedgehog signaling pathway antagonist cancer treatment
DK2016414T3 (en) * 2006-05-05 2015-12-07 Opexa Therapeutics T-cell vaccine
WO2008019290A2 (en) 2006-08-04 2008-02-14 Astrazeneca Ab Human antibodies to erbb 2
US7972594B2 (en) * 2006-11-13 2011-07-05 Immunovative Therapies Ltd. Ablative immunotherapy
WO2008061392A1 (fr) * 2006-11-22 2008-05-29 Hua Liu Procédé de préparation de populations cellulaires présentant une réponse immunitaire antitumorale
US20080147007A1 (en) * 2006-12-19 2008-06-19 Toby Freyman Delivery device with pressure control
US8148147B2 (en) 2007-01-24 2012-04-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
AU2008207735B2 (en) 2007-01-26 2013-10-03 University Of Louisville Research Foundation, Inc. Modification of exosomal components for use as a vaccine
WO2008098183A2 (en) * 2007-02-08 2008-08-14 The University Of Chicago Combination therapy for treating cancer
EP2650018A3 (en) 2007-05-14 2014-09-03 The University of Chicago Antibody-LIGHT fusion products for cancer therapeutics
EP2195650B1 (en) * 2007-09-12 2016-07-06 Yeda Research And Development Company Ltd. Methods of treating tumors in immune-privileged sites
US8114276B2 (en) 2007-10-24 2012-02-14 Baxter International Inc. Personal hemodialysis system
US9283266B2 (en) * 2008-02-28 2016-03-15 University Of Notre Dame Metastasis inhibition preparations and methods
BRPI0919473A2 (pt) 2008-09-26 2017-08-29 Oncomed Pharm Inc Agentes de ligação frizzled e usos dos mesmos
AU2009308707A1 (en) * 2008-10-31 2010-05-06 Biogen Idec Ma Inc. LIGHT targeting molecules and uses thereof
HUE032623T2 (hu) 2008-11-11 2017-10-30 Univ Michigan Regents Anti-CXCR1 kompozíciók és módszerek
CU23740A1 (es) * 2009-09-29 2011-12-28 Ct Ingenieria Genetica Biotech Método de obtención de una formulación de antígenos del virus de la hepatitis b
JP5816627B2 (ja) * 2009-10-27 2015-11-18 イミュニカム・エイビイ 抗原特異的ｔ細胞の増殖のための方法
JP6047403B2 (ja) * 2009-12-08 2016-12-21 ザ ボード オブ トラスティーズ オブ ザ ユニバシティ オブ イリノイズＴｈｅ Ｂｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｉｌｌｉｎｏｉｓ 幹細胞免疫変調の使用方法及び装置
US8846059B2 (en) 2009-12-08 2014-09-30 University Of Notre Dame Extracellular matrix adjuvant and methods for prevention and/or inhibition of ovarian tumors and ovarian cancer
US20110150934A1 (en) * 2009-12-18 2011-06-23 University Of Notre Dame Ovarian Tumor Tissue Cell Preparations/Vaccines for the Treatment/Inhibition of Ovarian Tumors and Ovarian Cancer
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
EP2548025A4 (en) * 2010-03-17 2013-09-25 Univ Michigan USE OF PHOTOEPITOPES FOR PROFILING AN IMMUNE REACTION
MX347515B (es) 2010-04-01 2017-04-28 Oncomed Pharmaceuticals Inc * Agentes que se unen al receptor encrespado y usos de los mismos.
WO2011129348A1 (ja) * 2010-04-13 2011-10-20 株式会社Ｒｅｉメディカル 癌組織由来細胞塊または癌細胞凝集塊から得られる癌治療用組成物およびそれを用いた免疫療法剤の製造方法ならびに免疫療法効果評価方法
EP2704741B1 (en) * 2011-05-03 2017-08-23 Immunovative Therapies, Ltd. Methods for handling biological drugs containing living cells
CA2836494C (en) * 2011-05-24 2023-01-03 Biontech Ag Individualized vaccines for cancer
CN104284680A (zh) 2011-12-15 2015-01-14 芝加哥大学 使用对受体的亲和力增加的突变型light分子用于癌症治疗的方法和组合物
CA2887711A1 (en) 2012-10-23 2014-05-01 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
WO2014121196A1 (en) 2013-02-04 2014-08-07 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
KR20160089356A (ko) * 2013-09-27 2016-07-27 백시노젠 인터내셔널 파트너스, 엘피 자가 종양 백신 및 방법
US11173205B2 (en) 2014-11-05 2021-11-16 Memorial Sloan Kettering Cancer Center Methods of selecting T cell line and donor thereof for adoptive cellular therapy
US20180055920A1 (en) * 2015-03-12 2018-03-01 University Of Iowa Research Foundation Vaccine, therapeutic composition and methods for treating or inhibiting cancer
EP3313419B1 (en) * 2015-06-26 2020-08-19 Memorial Sloan Kettering Cancer Center Methods of treating cmv retinitis by t cell therapy
WO2017023801A1 (en) 2015-07-31 2017-02-09 Regents Of The University Of Minnesota Intracellular genomic transplant and methods of therapy
US11219645B2 (en) 2015-11-18 2022-01-11 Duke University Tumor infiltrating lymphocytes for treatment of cancer
GB2605540B (en) 2016-10-18 2022-12-21 Univ Minnesota Tumor infiltrating lymphocytes and methods of therapy
WO2018138682A1 (en) 2017-01-26 2018-08-02 Immune Therapeutics Methods and compositions useful for treating cancer
JP2020530307A (ja) 2017-06-30 2020-10-22 インティマ・バイオサイエンス，インコーポレーテッド 遺伝子治療のためのアデノ随伴ウイルスベクター
KR102256337B1 (ko) * 2017-10-17 2021-05-26 (주)노터스생명과학 조직이식을 위한 세포배양액을 포함하는 면역억제제
US11446329B2 (en) 2017-11-01 2022-09-20 Restem Llc Natural killer cell adoptive transfer therapy for the elimination of senescent PBMCs, reduction of inflammatory cytokines and treatment of IBS
IL259392A (en) 2018-05-15 2018-08-01 Yeda Res & Dev Vaccination with cancer neo-antigens
FR3082730B1 (fr) * 2018-06-21 2022-04-22 Med Inn Pharma Methode de resolution de l'inflammation pro-tumorale a l'aide d'une preparation pharmaceutique
WO2023196232A1 (en) * 2022-04-04 2023-10-12 University Of Florida Research Foundation, Inc. Method of characterizing tumors
CN114984199A (zh) * 2022-04-19 2022-09-02 苏州尔生生物医药有限公司 一种基于癌症特异性t细胞的细胞系统、淋巴细胞药物及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192537A (en) 1984-03-30 1993-03-09 Cellcor Inc. Method of treating renal cell carcinoma using activated mononuclear cells, renal tumor antigen and cimetidine
US4828991A (en) 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
JP2639835B2 (ja) * 1988-11-30 1997-08-13 有限会社ジオリサーチ 免疫記憶細胞懸濁液の調製方法
US5229115A (en) * 1990-07-26 1993-07-20 Immunex Corporation Adoptive immunotherapy with interleukin-7
JPH06121672A (ja) * 1992-10-13 1994-05-06 Cellcor Inc 免疫反応性細胞の製造
US5820872A (en) * 1992-11-18 1998-10-13 Yale University Methods and compositions for improving the effectiveness of X-irradiation therapy for the treatment of an internal solid tumor
WO1994020120A1 (en) 1993-03-12 1994-09-15 Cellcor, Inc. In vitro assay measuring degree of activation of immune cells
CA2178950A1 (en) 1993-12-14 1995-06-22 Yajun Guo Tumor cell fusions and methods for use of such tumor cell fusions
US5759535A (en) 1994-05-13 1998-06-02 Research Corporation Technologies, Inc. Immunotherapeutic strategies for the treatment of cancer
JPH10504284A (ja) * 1994-06-14 1998-04-28 ザ ボード オブ トラスティーズ オブ レランド スタンフォード ジュニア ユニバーシティー 抗原パルス化樹状細胞によるｉｎ ｖｉｖｏ Ｔ細胞活性化法
DE4431401A1 (de) 1994-08-24 1996-02-29 Max Delbrueck Centrum Lebendvakzine gegen Tumorerkrankungen
CA2214503C (en) * 1995-03-17 2002-05-07 The Regents Of The University Of California Method for treating tumors
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine

Also Published As

Publication number Publication date
US6207147B1 (en) 2001-03-27
CA2267157C (en) 2005-05-31
CN1237909A (zh) 1999-12-08
EP0930887A2 (en) 1999-07-28
WO1998016238A3 (en) 1998-09-11
DE69718029D1 (de) 2003-01-30
NO991691L (no) 1999-06-09
DE69718029T2 (de) 2003-10-16
EP0930887B1 (en) 2002-12-18
JP2001509135A (ja) 2001-07-10
ATE229810T1 (de) 2003-01-15
AU743855B2 (en) 2002-02-07
BR9712988A (pt) 2000-10-24
WO1998016238A2 (en) 1998-04-23
CA2267157A1 (en) 1998-04-23
KR20000049096A (ko) 2000-07-25
NO991691D0 (no) 1999-04-09
AU4824297A (en) 1998-05-11

Similar Documents

Publication Publication Date Title
AR004445A1 (es) Una composicion inmunogenica, una dosis unitaria, un metodo para producir la composicion, un kit para producir la composicion, una poblacion de celulas,uso de dicha poblacion celular y una preparacion combinada
Sims Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer
Barth et al. The role of adjuvant therapy in melanoma management
ES2454990T3 (es) Quimioterapia e inmunoterapia simultáneas
Wu et al. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma
Mansour et al. Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMax®
EP0719150A4 (en) CELL VACCINE AND METHODS OF USE IN THE TREATMENT OF SOLID MALIGNANT TUMORS
CA2354046A1 (en) New cancer treatments
Ollila et al. Overview of melanoma vaccines: active specific immunotherapy for melanoma patients
AR068984A1 (es) Proceso para la obtencion de celulas presentadoras de antigenos activados, utiles en las terapias contra el cancer y enfermedades relacionadas del sistema inmunologico
Gregoire et al. Anti-cancer therapy using dendritic cells and apoptotic tumour cells: pre-clinical data in human mesothelioma and acute myeloid leukaemia
Yu et al. Therapeutic dendritic cell vaccines engineered with antigen‐biomineralized Bi2S3 nanoparticles for personalized tumor radioimmunotherapy
Zhang et al. Procyanidin, a kind of biological flavonoid, induces protective anti-tumor immunity and protects mice from lethal B16F10 challenge
Faries Intralesional immunotherapy for metastatic melanoma: the oldest and newest treatment in oncology
Tjoa et al. Progress in active specific immunotherapy of prostate cancer
Khan et al. Synthetic polyribonucleotides: current role and potential use in oncological practice
Mulé Dendritic cell‐based vaccines for pancreatic cancer and melanoma
CA2354045A1 (en) New cancer treatments
Durrant et al. Cancer vaccines entering Phase III clinical trials
ES2137172T3 (es) Vacunas antitumorales que comprenden celulas transfectadas con il-6.
Rosenthal et al. J-LEAPS vaccines elicit antigen specific Th1 responses by promoting maturation of type 1 dendritic cells (DC1)
Shahbaz et al. Breast Cancer Vaccination-An Envisioned Future
Hwang et al. Generation of Potent Cytotoxic T Lymphocytes Against Castration‐Resistant Prostate Cancer Cells by Dendritic Cells Loaded With Dying Allogeneic Prostate Cancer Cells
RU2203683C1 (ru) Способ иммунотерапии костно-мозговыми дендритными клетками больных солидными опухолями
Chavarria et al. Cancer vaccine’s multiverse and the future ahead

Legal Events

Date Code Title Description
FA Abandonment or withdrawal